Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database

The potent oral inhibitor of BCL2, venetoclax (VEN), used to treat adults with chronic lymphocytic leukaemia, has been approved in US for the treatment of naïve patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy and recently in Europe, too. However, the drug has been used fo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lucia Gozzo, Calogero Vetro, Serena Brancati, Laura Longo, Daniela Cristina Vitale, Giovanni Luca Romano, Elisa Mauro, Paolo Fabio Fiumara, Cinzia Maugeri, Marina Silvia Parisi, Ilaria Dulcamare, Bruno Garibaldi, Andrea Duminuco, Giuseppe Alberto Palumbo, Francesco Di Raimondo, Filippo Drago
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
venetoclax
acute myeloid leukemia
off-label
effectiveness
adverse event
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/2ff780c252104344b836dc38e573699f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/2ff780c252104344b836dc38e573699f

Ejemplares similares